Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drugmaker Elan
So what: In 2009, Elan sold the rights to its Alzheimer's' immunotherapy program to Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson
Now what: Bad news all around today, because there aren't many options available to treat Alzheimer's. Eli Lilly
Speaking specifically of Elan, which is best known for multiple sclerosis drug Tysabri, which it markets in partnership with Biogen Idec
Craving more input? Start by adding Elan to your free and personalized Watchlist so you can keep up on the latest news with the company.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Pfizer, as well as creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.